Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07656727
PHASE2

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Sponsor: BioAge Labs, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.

Official title: A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2026-06-11

Completion Date

2026-12

Last Updated

2026-06-18

Healthy Volunteers

No

Interventions

DRUG

Oral BGE-102

Capsules

DRUG

Oral Placebo Matching BGE-102

Capsules

Locations (13)

Site 108

Chandler, Arizona, United States

Site 115

Peoria, Arizona, United States

Site 110

Tucson, Arizona, United States

Site 100

Rogers, Arkansas, United States

Site 109

Maitland, Florida, United States

Site 102

Miami, Florida, United States

Site 104

Port Orange, Florida, United States

Site 103

Lexington, Kentucky, United States

Site 106

Rockville, Maryland, United States

Site 113

Kansas City, Missouri, United States

Site 112

Austin, Texas, United States

Site 101

San Antonio, Texas, United States

Site 105

San Juan, Puerto Rico